As a key molecule in mediating anti-tumor immunity, HMGN1 has the potential to be used in combination with checkpoint inhibitors or traditional cancer treatments such as surgery, chemotherapy, and radiotherapy to promote IFN-γ and cytotoxic T lymphocyte production to develop protective immunity against cancers (Yang et al. 2015; Couzin-Frankel 2013). Here, IFNG is linked to neoplasm.